Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions.
Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.
In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A.
The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally.
It has license and collaboration agreements with Sarepta Therapeutics; Ares TradingS. A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation.
The company was incorporated in 1996 and is headquartered in San Rafael, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 29, 24 | 0.55 Increased by +161.90% | 0.52 Increased by +5.77% |
| Aug 5, 24 | 0.56 Increased by +93.10% | 0.35 Increased by +60.00% |
| Apr 24, 24 | 0.46 Increased by +70.37% | 0.35 Increased by +31.43% |
| Feb 22, 24 | 0.18 Increased by +13.95 K% | 0.23 Decreased by -21.74% |
| Nov 1, 23 | 0.21 Increased by +625.00% | 0.23 Decreased by -8.70% |
| Jul 31, 23 | 0.29 Increased by +93.33% | 0.23 Increased by +26.09% |
| Apr 26, 23 | 0.27 Increased by +50.00% | 0.18 Increased by +50.00% |
| Feb 27, 23 | -0.00 Increased by +99.59% | -0.07 Increased by +98.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 745.74 M Increased by +27.27% | 106.08 M Increased by +162.72% | Increased by +14.22% Increased by +106.43% |
| Jun 30, 24 | 708.66 M Increased by +19.18% | 107.17 M Increased by +91.25% | Increased by +15.12% Increased by +60.46% |
| Mar 31, 24 | 648.83 M Increased by +9.43% | 88.66 M Increased by +74.35% | Increased by +13.66% Increased by +59.33% |
| Dec 31, 23 | 646.21 M Increased by +20.22% | 20.38 M Increased by +8.28 K% | Increased by +3.15% Increased by +6.91 K% |
| Sep 30, 23 | 585.97 M Increased by +15.95% | 40.38 M Increased by +707.01% | Increased by +6.89% Increased by +623.49% |
| Jun 30, 23 | 594.60 M Increased by +11.39% | 56.04 M Increased by +102.57% | Increased by +9.42% Increased by +81.86% |
| Mar 31, 23 | 592.95 M Increased by +14.17% | 50.85 M Decreased by -57.90% | Increased by +8.58% Decreased by -63.13% |
| Dec 31, 22 | 537.54 M Increased by +19.50% | -249.00 K Increased by +99.57% | Decreased by -0.05% Increased by +99.64% |